News | News By Subject | News by Disease News By Date | Search News

Alzheimer's Disease News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
The 7 Worst Clinical Disasters of 2016     12/27/2016
Acadia (ACAD) Stock Screams Upward; Primary Endpoint Met in Phase II Study of Pimavanserin for Alzheimer’s     12/21/2016
Investors Sigh With Relief as Biogen (BIIB)'s Alzheimer's Drug Delivers in Early-Stage Study     12/15/2016
As Biogen (BIIB)'s Drug Shines, Eli Lilly (LLY) Releases Detailed Results of Its Own Failure Solanezumab     12/9/2016
All Eyes Will Be on Biogen (BIIB) and Its Much-Anticipated Alzheimer's Data Tomorrow     12/9/2016
Fear of Layoffs Loom Over Eli Lilly (LLY) Employees After Alzheimer's Setback     12/1/2016
Devastation Hits as Eli Lilly (LLY)'s Alzheimer's Drug Flunks Late-Stage Study, Shares Tank     11/29/2016
Investors Remain Bullish Over Biogen (BIIB)'s Risky Alzheimer's Drug Despite Eli Lilly (LLY) Setback     11/28/2016
Former Allergan (AGN) Exec Who Now Helms Chase Pharma Inks $1 Billion Pact With Brent Saunders and His New Gang     11/28/2016
5 Drug Giants That Could Dominate the $13 Billion Alzheimer's Market     11/23/2016
As Eli Lilly (LLY)'s ALZ Data Looms, Here Are Some Things Investors Need to Know     11/18/2016
Investors Hold Their Breath for the "Most Important Event in Biotech"—Here are 5 Stocks to Watch     11/18/2016
3 Reasons That Make Biogen (BIIB) the King of a Crumbling Empire     11/14/2016
Merck & Co. (MRK)'s Alzheimer's Contender Wows in Human Clinical Trial     11/3/2016
Why Biogen (BIIB)'s Fate May Depend on Eli Lilly (LLY)'s Alzheimer's Data     10/27/2016

News from Around the Web
From Psychedelics To Alzheimer's, 2016 Was A Good Year For Brain Science     1/3/2017
Following Eli Lilly (LLY)'s Failure, What's Next In Alzheimer's Treatments?     12/19/2016
Treating Alzheimer’s Disease With Brain Waves, Study Published In Nature     12/9/2016
Catalyst Driver For PDL BioPharma (PDLI) Is Coming     11/18/2016
Alzheimer’s Didn’t Cause Memory Loss For These Superaging 90-Year Olds, Northwestern University Feinberg School of Medicine Study     11/17/2016
Eli Lilly (LLY)'s Solanezumab And The History Of The Future Of Treating Alzheimer's Disease     11/11/2016
Baylor College of Medicine Take First Steps Toward A Preventative Alzheimer's Pill     10/25/2016
University of Pennsylvania Psychiatrist Questions Whether Antidepressants Prevent Alzheimer's     10/10/2016
Genetic Score Predicts Age-Related Risk Of Alzheimer's Disease, University of California, San Diego (UCSD) Study Says     10/5/2016
Eli Lilly (LLY)'s Alzheimer's Drug Could Potentially Bring in Billions     9/28/2016
Getting Real About An Alzheimer's Cure     9/9/2016
Lancaster University Scientists Link Air Pollution To Alzheimer's     9/6/2016
Shark Fins And Meat Contain High Levels Of Neurotoxins Linked To Alzheimer's, University of Miami Study Reveals     8/30/2016
Use It Or Lose It: Stopping Exercise Decreases Brain Blood Flow, University of Maryland Study Shows     8/30/2016
Gene Wilder Died Of Alzheimer’s. His Family Explains Why They Didn’t Disclose His Diagnosis     8/30/2016

Press Releases
Saladax Biomedical Inc. (SBI) Release: Company Licenses Alzheimer’s Diagnostic Tests To Siemens Healthineers (SI)     1/18/2017
Selonterra Release: Biotech Publishes Novel Proprietary Mechanism for APOE4 In Alzheimer’s Disease     1/17/2017
Probiodrug AG Announces Completion Of Recruitment For The SAPHIR Phase 2a Study Of Glutaminyl Cyclase Inhibitor PQ912 In Early Alzheimer's Disease Patients     1/9/2017
NeuroGenetic Pharmaceuticals, Inc. Completes Phase 1 Clinical Trials For NGP 555 To Treat And Prevent Alzheimer’s Disease; Shown As Safe And Well-Tolerated In Healthy Volunteers     1/9/2017
Recombinant Technologies, LLC Release: Company Receives Phase II SBIR Grant To Develop AmyTrap for Treatment of Alzheimer’s Disease     1/6/2017
ProMis Neurosciences Declares PMN 310 Its First Lead Product For Development In Alzheimer's Disease     1/5/2017
Neuronix Ltd. Reports Positive Results From Its Multi-Center Alzheimer's Study At The Clinical Trials In Alzheimer's Disease (CTAD) Conference     1/4/2017
Alzamend Neuro Launches Regulation A+ Tier II SEC Qualified Offering     1/4/2017
Axsome (AXSM) Receives FDA Clearance Of IND For Phase II/III Trial Of AXS-05 In Alzheimer’s Disease Agitation     1/3/2017
Tetra Discovery Partners Announces Positive Results From Phase 1 Studies Of Cognition Drug Candidate, BPN14770     12/19/2016
Karuna And PureTech Announce Positive Results From Tolerability Proof-of-Concept Study Of KarXT, Being Developed For Schizophrenia And Alzheimer's     12/15/2016
Cognition Therapeutics Initiates US Clinical Testing Of CT1812, A Novel Small Molecule For The Potential Treatment Of Alzheimer's Disease     12/13/2016
Axovant (AXON) Unveils New Data Analysis Showing Addition Of Intepirdine To Standard Therapy May Help People With Alzheimer's Disease Maintain Independence Longer     12/12/2016
Eisai Inc. (ESALF.PK) Presents Data On BACE Inhibitor Elenbecestat (E2609) At 9th Clinical Trials On Alzheimer's Disease (CTAD) Meeting     12/12/2016
Eli Lilly (LLY) Takes Another Plunge Into Alzheimer's, This Time With AstraZeneca PLC (AZN)     12/9/2016

//-->